Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.0549
Schlusskurs vom Vortag:
$0.0549
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$14.55M
Einnahmen:
$175.04M
Nettoeinkommen (Verlust:
$-44.52M
KGV:
0.00
EPS:
-0.18
Netto-Cashflow:
$-56.05M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$0.8334
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile
Firmenname
Adaptimmune Therapeutics Plc Adr
Sektor
Branche
Telefon
44 1235 430000
Adresse
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
Vergleichen Sie ADAP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADAP
Adaptimmune Therapeutics Plc Adr
|
0.00 | 14.55M | 175.04M | -44.52M | -56.05M | -0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-06-26 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-07-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-30 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-03-24 | Eingeleitet | Bryan Garnier | Buy |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-09 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-05-28 | Eingeleitet | Barclays | Underweight |
| 2020-04-22 | Eingeleitet | Mizuho | Neutral |
| 2019-08-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-05-31 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-30 | Fortgesetzt | Citigroup | Buy |
| 2019-05-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2017-03-17 | Eingeleitet | Wells Fargo | Market Perform |
| 2016-10-24 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2016-09-30 | Eingeleitet | Raymond James | Outperform |
| 2016-02-25 | Eingeleitet | Citigroup | Buy |
| 2015-06-01 | Eingeleitet | BofA/Merrill | Neutral |
| 2015-06-01 | Eingeleitet | Guggenheim | Buy |
| 2015-06-01 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Adaptimmune Therapeutics Plc Adr Aktie (ADAP) Neueste Nachrichten
How Adaptimmune Therapeutics plc (Common Stock) (473A) stock performs during market turbulence2025 EndofYear Setup & Technical Pattern Based Signals - newser.com
Adaptimmune Therapeutics PLC (ADAPY) Stock PDF (Updated: 2025/11/05) - GuruFocus
Adaptimmune Therapeutics PLC Sponsored ADR Financial Disclosures & SEC Filings - TradingView
Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback? - ts2.tech
Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer - GlobeNewswire Inc.
Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Adaptimmune stock plunges after announcing Nasdaq delisting plans By Investing.com - Investing.com Philippines
Adaptimmune stock plunges after announcing Nasdaq delisting plans - Investing.com India
Adaptimmune to delist from Nasdaq amid cost-cutting efforts - Investing.com
Pre-Market Movers: MIRA, ADAP, GNPX Swing Big - RTTNews
Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp? - ts2.tech
Pre-Market Titans: TTRX, BJDX & UPC Set The Pace - RTTNews
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real? - ts2.tech
Morning Market Movers: FEMY, PALI, COSM, Seeing Big Swings - RTTNews
Adaptimmune Granted Exception Period by Nasdaq Panel - The Globe and Mail
Morning Market Movers: MRM, LEXX, WOLF See Big Swings - RTTNews
Stocks Moving Premarket: PEPG, WOK, ICU, And Other Gainers & Losers - RTTNews
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC - Yahoo Finance
Must-Watch Streaming Stocks Poised to Gain From Content Boom - Yahoo Finance
Is Hesai Group Sponsored ADR (HSAI) Outperforming Other Auto-Tires-Trucks Stocks This Year? - Yahoo Finance
Lenovo Finds 65% of IT Leaders Admit Their Defenses Can’t Withstand AI Cybercrime - Yahoo Finance
Why the Market Dipped But Li Auto Inc. Sponsored ADR (LI) Gained Today - Yahoo Finance
What Does Wall Street Think About Li Auto Inc. (LI)? - Yahoo Finance
Vestas Wind Systems AS ADR (VWDRY) Wind Turbines Orders on the Rise - Yahoo Finance
The Zacks Analyst Blog Highlights Walmart, Alibaba, Shell, Omega Flex and Weyco - Yahoo Finance
Investors Take Advantage Of 15.76% Gain In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - stocksregister.com
What Is Going On With Top KingWin Ltd (NASDAQ: WAI)? - stocksregister.com
Rio Tinto plc ADR Common Stock (RIO) Restructures to Focus on Profitable Assets - Yahoo Finance
Zacks.com featured highlights include Halozyme Therapeutics, Phibro, Leidos and PDD Holdings - Yahoo Finance
Adaptimmune Therapeutics CFO Wood sells $950 in shares - Investing.com
Nio Inc. ADR (NIO) Upgraded to ‘Overweight’ at JPMorgan on Strong Vehicle Demand - Yahoo Finance
Earnings call transcript: Adaptimmune Q2 2025 shows revenue beat, stock dips - Investing.com
Adaptimmune director Behbahani sells shares worth $229,171 - Investing.com
Are Investors Undervaluing ENGIESponsored ADR (ENGIY) Right Now? - Yahoo Finance
Adaptimmune Faces Nasdaq Delisting Notice Amid Compliance Issues - MSN
Adaptimmune Sales Jump 59 Percent - sharewise.com
Is Piedmont Lithium Inc.Sponsored ADR (PLL) Stock Outpacing Its Basic Materials Peers This Year? - Yahoo Finance
ADAP’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - Yahoo Finance
Wall Street Today: Dow, Nasdaq, S&P 500 open higher as investors focus on optimism over potential US Fed rate cut - Mint
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Ecor1 capital sells Adaptimmune Therapeutics (ADAP) shares for $6.89m - Investing.com India
Adaptimmune stock rating downgraded by H.C. Wainwright after asset sale - Investing.com South Africa
Adaptimmune Therapeutics stock plunges after selling cell therapy assets By Investing.com - Investing.com India
Adaptimmune Therapeutics stock plunges after selling cell therapy assets - Investing.com
Adaptimmune sells cell therapy assets to US WorldMeds for $55 million - Investing.com
XPeng Inc. Sponsored ADR (XPEV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect - Yahoo Finance
Mizuho downgrades Adaptimmune stock on solvency concerns - Investing.com
Financial Metrics Unveiled: MARA Holdings Inc (MARA)’s Key Ratios in the Spotlight - DWinneX
Best Momentum Stocks to Buy for June 12th - Yahoo Finance
Finanzdaten der Adaptimmune Therapeutics Plc Adr-Aktie (ADAP)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.44%
0.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):